BioPharmSignal logoBioPharmSignal

Biotech News

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Aziyo Biologics (AZYO)Aziyo BiologicsEarnings

– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference call today at 5:00 p.m. ET / 2:00 p.m.

Related news

AZYOAziyo Biologics2026-01-12 13:00 EST

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

AZYOAziyo Biologics2026-05-14 20:06 EST

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

View all latest news

Aziyo Biologics

Aziyo Biologics is a regenerative medicine company focused on implantable biologic products used in surgery and tissue repair. Its business is centered on specialty biologics rather than classic biotech drug development.

Recent company news

AZYOAziyo Biologics2026-07-31 12:00 EST

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

AZYOAziyo Biologics2026-07-16 20:05 EST

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

AZYOAziyo Biologics2026-06-11 20:05 EST

Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

AZYOAziyo Biologics2026-05-18 20:05 EST

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

AZYOAziyo Biologics2026-05-14 20:06 EST

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States